摘要
脓毒症是当前重症监护病房患者的主要死亡原因,同时其幸存者也会出现长期的免疫抑制和高复发感染。目前对脓毒症的临床治疗还是以抗生素、静脉补液和血管加压为主,尚无针对性的药物治疗。但随着抗生素耐药率不断升高,免疫治疗作为一种新的治疗方式备受期待。脓毒症患者多伴有急性白细胞免疫功能异常障碍和免疫抑制,这可能是患者发病率和死亡率不断增加的重要危险因素。靶向抑制特定细胞表面抑制性免疫检查点受体和配体,如程序性死亡受体-1(PD-1)、程序性死亡-配体1(PD-L1)等靶点能够提高宿主对感染的抵抗力。主要对PD-1和PD-L1在脓毒症免疫反应中的作用及相关机制的研究进展进行总结,为其在脓毒症治疗中的进一步应用提供理论依据。
Sepsis is currently the leading cause of death in the intensive care unit,and its survivors also experience long-term immunosuppression and high rates of recurrent infections.At present,the clinical treatment of sepsis is still based on antibiotics,intravenous rehydration,and vasopressors,and there is no targeted drug treatment.However,as the rate of antibiotic resistance continues to increase,immunotherapy is highly anticipated as a new treatment.Patients with sepsis are often accompanied by acute leukocyte immune dysfunction and immunosuppression,which may be an important risk factor for the increasing morbidity and mortality of patients.Targeted inhibition of specific cell surface inhibitory immune checkpoint receptors and ligands,such as programmed death receptor-1(PD-1),programmed death-ligand 1(PD-L1),and other targets,can improve the host’s resistance to infection.In this paper,the research progress of PD-1 and PD-L1 in the immune response to sepsis was summarized to provide a theoretical basis for their further application in the treatment of sepsis in the future.
作者
郦弈帆
张丹颖
王梦晴
林兆奋
Li Yifan;Zhang Danying;Wang Mengqing;Lin Zhaofen(Department of Emergency and Critical Care Medicine,Shanghai Changzheng Hospital,Shanghai 200003,China)
出处
《国际生物医学工程杂志》
CAS
2023年第3期270-274,共5页
International Journal of Biomedical Engineering
